Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization
Veronica Di Sarno, Gianluigi Lauro, Simona Musella, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113863-113863
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 146
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease
Haozhou Tan, Yanmei Hu, Prakash D. Jadhav, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7561-7580
Open Access | Times Cited: 118
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 52
Recent advance in the development of N-heterocyclic derivatives as anti-SARS-CoV-2 inhibitors: A review
Walid Ettahiri, Mohamed Adardour, Siham Alaoui, et al.
Phytochemistry Letters (2024) Vol. 61, pp. 247-269
Closed Access | Times Cited: 10
Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization
Tania Ciaglia, Vincenzo Vestuto, Veronica Di Sarno, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116128-116128
Open Access | Times Cited: 9
Synthesis of 5-heptadecyl-4H-1,2,4-triazole incorporated indole moiety: Antiviral (SARS-CoV-2), antimicrobial, and molecular docking studies
Hayam A. Abd El Salam, Heba M. Abo‐Salem, Omnia Kutkat, et al.
Journal of Molecular Structure (2024) Vol. 1303, pp. 137517-137517
Closed Access | Times Cited: 8
Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease
Vasundara Srinivasan, H. Brognaro, Prince R. Prabhu, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 35
Re-Exploring the Ability of Common Docking Programs to Correctly Reproduce the Binding Modes of Non-Covalent Inhibitors of SARS-CoV-2 Protease Mpro
Davide Bassani, Matteo Pavan, Giovanni Bolcato, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 180-180
Open Access | Times Cited: 23
Development of spiro-3-indolin-2-one containing compounds of antiproliferative and anti-SARS-CoV-2 properties
Nehmedo G. Fawazy, Siva S. Panda, Ahmed Mostafa, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 19
Discovery of PLpro and Mpro Inhibitors for SARS-CoV-2
Ana C. Puhl, André S. Godoy, G.D. Noske, et al.
ACS Omega (2023) Vol. 8, Iss. 25, pp. 22603-22612
Open Access | Times Cited: 12
Targeting SARS-CoV-2 nonstructural protein 3: Function, structure, inhibition, and perspective in drug discovery
Xin Li, Yongcheng Song
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103832-103832
Open Access | Times Cited: 11
Indole-Based Compounds as Potential Drug Candidates for SARS-CoV-2
Adel S. Girgis, Siva S. Panda, Benson M. Kariuki, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6603-6603
Open Access | Times Cited: 10
Main and papain-like proteases as prospective targets for pharmacological treatment of coronavirus SARS-CoV-2
Larysa V. Yevsieieva, Kateryna Lohachova, Alexander Kyrychenko, et al.
RSC Advances (2023) Vol. 13, Iss. 50, pp. 35500-35524
Open Access | Times Cited: 10
PharmaCore: The Automatic Generation of 3D Structure-Based Pharmacophore Models from Protein/Ligand Complexes
Simona De Vita, Ester Colarusso, Maria Giovanna Chini, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 10, pp. 4263-4276
Closed Access | Times Cited: 3
Molecular insights into the in silico discovery of corilagin from Terminalia chebula as a potential dual inhibitor of SARS-CoV-2 structural proteins
Sushma Pradeep, Shashank M. Patil, Chandan Dharmashekara, et al.
Journal of Biomolecular Structure and Dynamics (2022) Vol. 41, Iss. 20, pp. 10869-10884
Closed Access | Times Cited: 15
Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2
Simone Di Micco, Rahila Rahimova, Marina Sala, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114857-114857
Open Access | Times Cited: 14
Design of inhibitors of SARS-CoV-2 papain-like protease deriving from GRL0617: Structure–activity relationships
Lukáš Kerti, Vladimı́r Frecer
Bioorganic & Medicinal Chemistry (2024), pp. 117909-117909
Open Access | Times Cited: 2
SAR based Review on Diverse Heterocyclic Compounds with Various Potential Molecular Targets in the Fight against COVID-19: A Medicinal Chemist Perspective
Anish Madan, Mansi Garg, Garvit Satija, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 14, pp. 1319-1339
Closed Access | Times Cited: 6
New Chemicals Suppressing SARS-CoV-2 Replication in Cell Culture
А.В. Сулимов, Ivan Ilin, Danil Kutov, et al.
Molecules (2022) Vol. 27, Iss. 17, pp. 5732-5732
Open Access | Times Cited: 9
Discovery of natural‐derived Mpro inhibitors as therapeutic candidates for COVID‐19: Structure‐based pharmacophore screening combined with QSAR analysis
Mohammad A. Khanfar, Nada Salaas, Reem Abumostafa
Molecular Informatics (2023) Vol. 42, Iss. 4
Closed Access | Times Cited: 5
SARS-COV-2 Coronavirus Papain-like Protease PLpro as an Antiviral Target for Inhibitors of Active Site and Protein–Protein Interactions
П. В. Ершов, Е.O. Yablokov, Yuri V. Mezentsev, et al.
BIOPHYSICS (2022) Vol. 67, Iss. 6, pp. 902-912
Open Access | Times Cited: 8
Arylamines QSAR-Based Design and Molecular Dynamics of New Phenylthiophene and Benzimidazole Derivatives with Affinity for the C111, Y268, and H73 Sites of SARS-CoV-2 PLpro Enzyme
Gianfranco Sabadini, Marco Mellado, Cesar A. Morales, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 606-606
Open Access | Times Cited: 1
Screening, Synthesis and Biochemical Characterization of SARS-CoV-2 Protease Inhibitors
Martynas Bagdonas, Kamilė Čerepenkaitė, Aurelija Mickevičiūtė, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13491-13491
Open Access | Times Cited: 2
Chemically modified antiviral peptides against SARS‐CoV‐2
Michael Quagliata, Anna Maria Papini, Paolo Rovero
Journal of Peptide Science (2023)
Open Access | Times Cited: 2
CROMATIC: Cross-Relationship Map of Cavities from Coronaviruses
Lydia Siragusa, Gabriele Menna, Fabrizio Buratta, et al.
Journal of Chemical Information and Modeling (2022) Vol. 62, Iss. 12, pp. 2901-2908
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top